Shareholders clear the merger; closing still hinges on regulators

The vote removes a key procedural risk, but was largely expected. Axalta shareholders overwhelmingly approved the previously announced all-stock merger, and AkzoNobel shareholders approved it the same day (Exhibit 99.1 — Merger approval). Both votes were already scheduled conditions to closing, so this is progress rather than a change to the deal’s economics or terms.

The transaction is not yet cleared to close. Required regulatory approvals and other customary conditions remain outstanding, and management repeated the existing late-2026 to early-2027 completion window (Exhibit 99.1 — Merger approval). The filing provides no new detail on regulatory timing, remedies, synergies, or integration execution.

Net: de-risking, not a fresh upside catalyst. The shareholder hurdle is now behind both companies, modestly reducing deal-break risk, but the filing leaves the central uncertainty—regulatory approval and final closing—unchanged. Management’s reference to a “record second quarter” is favorable framing, not new financial disclosure in this filing (Exhibit 99.1 — CEO remarks).